PCSK9 inhibitors added to statins in acute ischaemic stroke: promising but preliminary

Design

Systematic review and meta-analysis of randomised trials with GRADE assessment

Population

Patients with acute ischaemic stroke receiving statins, with or without a PCSK9 inhibitor

Primary outcome

Functional independence (mRS 0 to 2) and recurrent ischaemic stroke

Effect

mRS 0 to 2 OR 2.17 (95% CI 1.29 to 3.64); recurrence OR 0.33 (0.16 to 0.69)

This meta-analysis of randomised trials compared a PCSK9 inhibitor plus statin with statin alone in patients with acute ischaemic stroke. Compared with statin monotherapy, the combination was associated with more patients reaching functional independence (modified Rankin Scale 0 to 2: odds ratio 2.17, 95% CI 1.29 to 3.64, I-squared 48%) and fewer recurrent ischaemic strokes (OR 0.33, 0.16 to 0.69, I-squared 0%). NIHSS scores did not differ significantly, with very high heterogeneity driven largely by one study. Liver function abnormalities, major adverse cardiovascular events and total adverse events were comparable.

Certainty of evidence by GRADE was moderate for functional independence, low for recurrent stroke and safety outcomes, and very low for NIHSS. The authors describe the evidence as preliminary and call for larger, adequately powered trials.

The number of trials and patients is small, and a recurrence odds ratio of 0.33 is much larger than most secondary prevention effects, which may reflect the small number of studies. Current guidelines are unchanged by this analysis.

• Do not start a PCSK9 inhibitor for acute stroke on the strength of this analysis.
• Functional independence was higher (OR 2.17), but with moderate certainty and some heterogeneity.
• A recurrence odds ratio of 0.33 is larger than most secondary prevention effects, from a small evidence base.
• Existing indications for lipid-lowering after stroke are unchanged.

Why it matters

It asks whether aggressive lipid lowering in the acute phase changes recovery, not only long-term recurrence.

Don't overread it

The evidence for recurrence is rated low certainty and the authors call it preliminary.

The statistics, in plain English

The I-squared figure shows how much of the variation between trials is not explained by chance; 0% for recurrence suggests consistency, while 98% for NIHSS means those results are not combinable in a useful way.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.